Table 2.
Pre- and 12 mo follow-up outcomes for control (n=225) and intervention (n=188) groups
| Pre % (n) | Post (12mo) % (n) | AORa | (95% CI) | p-valuea | |
|---|---|---|---|---|---|
| Adherence past mo (VAS) ≥ 95% | |||||
| Intervention | 0 (0) | 83.5 (157)* | 1.86 | (1.09 – 3.15) | .022 |
| Control | 0 (0) | 73.8 (166) | (ref) | ||
| No Tx interruptions past 6 mob | |||||
| Intervention | 5.3 (10) | 79.8 (150) | 1.43b | (0.87 – 2.36) | .163 |
| Control | 3.1 (7) | 72.4 (163) | (ref) | ||
| No family-level adherence barriersb | |||||
| Intervention | 75.5 (142) | 92.0 (173) | 0.93 | (0.44 – 1.97) | 0.841 |
| Control | 72.0 (162) | 92.0 (207) | (ref) | ||
| No individual adherence barriers | |||||
| Intervention | 4.8 (9) | 62.2 (117)*** | 2.33 | (1.51 – 3.62) | <.001 |
| Control | 3.6 (8) | 45.3 (102) | (ref) | ||
| No social/structural adherence barriers | |||||
| Intervention | 12.8 (24) | 64.9 (122) | 1.49 | (0.96 – 2.32) | 0.078 |
| Control | 12.4 (28) | 59.1 (133) | (ref) | ||
| No regimen/clinic adherence barriers | |||||
| Intervention | 18.1 (34) | 78.2 (147) | 1.07 | (0.65 – 1.77) | 0.795 |
| Control | 23.1 (52) | 76.9 (173) | (ref) | ||
| No clinic attendance barriers | |||||
| Intervention | 57.5 (108) | 83.0 (156)** | 2.01 | (1.20 – 3.38) | 0.008 |
| Control | 62.7 (141) | 70.7 (159) | (ref) | ||
| Undetectable VLc | |||||
| Intervention | 46.8 (88) | 52.7 (99)* | 1.98 | (1.22 – 3.23) | .006 |
| Control | 46.8 (102) | 40.8 (89) | (ref) |
*
p< 0.05;
**
p<0.01;
***
p≤ 0.001
a
Adjusted for gender and location for all outcomes, as well as for pre-intervention value on outcomes with pre-intervention variability.
b
Used Firth’s penalized maximum likelihood estimation to address complete separation problem
c
control group: missing data for 1 case at BL and 6 more cases at 12mo; hence results based on n=225–7=218; intervention group: no missing data, n=188.